Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02621333
Other study ID # HenanCH003
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 2015
Est. completion date September 2018

Study information

Verified date February 2020
Source Henan Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, open, multicenter phase Ⅱ study to evaluate the efficacy of cytokine-induced killer cells combined chemotherapy in stage Ⅳ naive EGFR wild-type lung adenocarcinoma.


Description:

There is still no great improvement in advanced EGFR wild-type lung adenocarcinoma although great progress was made in treatment of non-small cell lung cancer. It's necessary to explore the treatment mode of this kind of patients. As the progress was made in tumor immunity and immunotherapy, more and more cancer therapists accept the treatment model of chemotherapy combined immunotherapy. And now chemotherapy combined autologous CIK cells is one kind of common treatment model in some countries. Investigators try to evaluate the efficacy and safety of this kind of treatment model in patients with stage Ⅳ naive EGFR wild-type lung adenocarcinoma.


Recruitment information / eligibility

Status Terminated
Enrollment 280
Est. completion date September 2018
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Diagnosed as stage ? naive EGFR wild-type lung adenocarcinoma by image, tissue and/or cytology; or relapse after operation (if the patient received adjuvant chemotherapy and the interval between the last chemotherapy and relapse is at least six months. The detection method of EGFR mutation is ARMS. 2. EML4-ALK fuse gene is negative and the detection of EML4-ALK is FISH or ventana IHC. 3. There should be at least one measurable lesions (by CT or MRI) 4. No other cancer history ( except skin squamous cell carcinoma after surgery) 5. Age between 18 and 75 years old 6. World health organization- Eastern Cooperative Oncology Group Performance Status 0-1 7. Life expectancy more than 3 months and can be followed-up 8. Patients must have adequate organ and marrow functions as defined below: white blood cells: more than 3.5×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than 80×109/L, Hemoglobin more than 90g/L, Serum total bilirubin less than 1.5 folds of the upper normal limit (ULN), Serum glutamic-oxal (o) acetic transaminase: less than 2.5×ULN (if there is liver metastasis less than 5×ULN); Serum creatinine: less than 1.0×ULN, Prothrombin time, Active partial thromboplastin time, Fibrinogen, Thrombin time are in normal ranges. 9. Women of child-bearing period must take effective contraceptive measures during all the time of study. During the period of study the results of blood and urine pregnancy test should be negative. 10. Men should take effective contraceptive measures from the beginning of therapy to one month after the last cycle of chemotherapy. 11. Willing to comply with the ban and constraints for this study protocol specified. 12. Informed consent and willing to participate in this study. Exclusion Criteria: 1. Accepted other study drugs 30 days before the beginning of this study. 2. Brain metastases with clinical symptoms ( with exception of being controlled after radiation) 3. Active viral or bacterial infection and can't be controlled with appropriate anti-infection treatment 4. Known as HIV infection, syphilis serology reaction positive, active hepatitis B virus or hepatitis C virus infection 5. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not be coped with study treatment and monitoring requirements. 6. Known allergy to any kind of component of study drugs 7. Active rheumatic diseases 8. Organ transplant recipients 9. Poor compliance 10. Pregnant women 11. Lactating women

Study Design


Intervention

Biological:
CIK
platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2,D1;combined cisplatin 25mg/m2,D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
Drug:
chemotherapy
platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2,D1;combined cisplatin 25mg/m2,D1-3 or carboplatin AUC=5, D1.

Locations

Country Name City State
China Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university ZhengZhou Henan

Sponsors (15)

Lead Sponsor Collaborator
Henan Cancer Hospital 150th Hospital of PLA, Anyang Regional Hospital, First Affiliated Hospital of Nanyang Medical College, First People's Hospital of Shangqiu, Hebei Medical University Fourth Hospital, Henan Provincial People's Hospital, Jiaozuo Tumor Hospital, Nanyang Central Hospital, Puyang Oil Field General Hospital, Shanxi Dayi Hospital, Shenma Medical Group General Hospital, Tangshan People's Hospital, The 152th Central Hospital of PLA, Xinyang Central Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33. doi: 10.1007/s00262-012-1260-2. Epub — View Citation

Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol. 2015 Sep;28(1):22-8. doi: 10.1016/j.intimp.2015.05.021. Epub 2015 May 23. Review. — View Citation

Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011 Oct;60(10):1497-502. doi: 10.1007/s00262-011-1060- — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival time overall survival time aims at from date of randomization until the date of death from any cause, up to 36 months from the day of randomization to the day of death, up to 36 months
Secondary time to progression time to progression points to from date of randomization until the date of first documented progression, up to 24 months from the day of randomization to the day of first detecting progression, up to 24 months
Secondary objective response rate the partion of overall remission in total proportion one year
See also
  Status Clinical Trial Phase
Recruiting NCT02898857 - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma N/A
Completed NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting NCT01249066 - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma N/A
Not yet recruiting NCT04482829 - TCM in the Treatment of Lung Adenocarcinoma N/A
Recruiting NCT04929041 - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Phase 2/Phase 3
Terminated NCT04691375 - A Study of PY314 in Subjects With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02282267 - Blood Detection of EGFR Mutation For Iressa Treatment N/A
Not yet recruiting NCT01942629 - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas N/A
Recruiting NCT01482585 - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy N/A
Recruiting NCT03376737 - Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Phase 2
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting NCT04937283 - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm N/A
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed NCT02093000 - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma N/A
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Terminated NCT04682431 - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05736991 - Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Enrolling by invitation NCT05136014 - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Recruiting NCT05266846 - Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK Phase 2